FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kelderman Kim		 2. Issuer Name and Ticker or Trading Symbol

BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Pres. Diagnostics & Genom
(Last)          (First)          (Middle)

614 MCKINLEY PLACE NE		 3. Date of Earliest Transaction (MM/DD/YYYY)

8/5/2020
(Street)

MINNEAPOLIS, MN 55413
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock         1668 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units  (1)           (2) (2)Common Stock 1667  1667 D  
Stock Options (Right to Buy) $150.78            (3)5/1/2025 Common Stock 2652  2652 D  
Stock Options (Right to Buy) $150.78            (4)5/1/2025 Common Stock 7348  7348 D  
Restricted Stock Units  (1)           (5) (5)Common Stock 1691  1691 D  
Stock Options (Right to Buy) $177.32            (6)8/8/2025 Common Stock 12044  12044 D  
Stock Options (Right to Buy) $177.32            (5)8/8/2025 Common Stock 9033  9033 D  
Restricted Stock Units  (1)           (7) (7)Common Stock 2363  2363 D  
Stock Options (Right to Buy) $190.41            (7)8/7/2026 Common Stock 11961  11961 D  
Stock Options (Right to Buy) $190.41            (8)8/7/2026 Common Stock 15948  15948 D  
Restricted Stock Units  (1)8/5/2020  A   2015     (9) (9)Common Stock 2015 $0 2015 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   8991     (9)8/5/2027 Common Stock 8991 $0 8991 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   11988     (10)8/5/2027 Common Stock 11988 $0 11988 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   8325     (11)8/5/2027 Common Stock 8325 $0.0 8325 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   8325     (12)8/5/2027 Common Stock 8325 $0.0 8325 D  
Explanation of Responses:
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) 1,667 restricted stock units vest on 5/1/2021.
(3) Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
(4) Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
(5) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(6) Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.
(7) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(8) Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.
(9) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
(11) Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
(12) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Kelderman Kim
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413

Pres. Diagnostics & Genom
Signatures
/s/ Brenda S. Furlow as Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.8/7/2020
**Signature of Reporting PersonDate
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bio Techne Charts.